{
    "clinical_study": {
        "@rank": "55148", 
        "arm_group": {
            "arm_group_label": "Cohort"
        }, 
        "brief_summary": {
            "textblock": "This prospective, multicenter, observational study will evaluate on-treatment predictors of\n      response in patients with HBeAg positive or HBeAg negative chronic hepatitis B receiving\n      treatment with Pegasys (peginterferon alfa-2a) in accordance with local labelling and the\n      summary of product characteristics. Data will be collected from patients for the duration of\n      their treatment and for up to 24 weeks thereafter."
        }, 
        "brief_title": "An Observational Study of Pegasys (Peginterferon Alfa-2a) in Patients With HBeAg Positive or HBeAg Negative Chronic Hepatitis B", 
        "completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Hepatitis B, Chronic", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis B", 
                "Hepatitis, Chronic", 
                "Hepatitis B, Chronic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult patients, >/= 18 years of age\n\n          -  HBeAg positive or HBeAg negative hepatitis B with or without cirrhosis\n\n          -  Elevated ALT >ULN (upper limit of normal) but </=10 x ULN according to local label\n\n        Exclusion Criteria:\n\n          -  Contra-indications to Pegasys as detailed in the label\n\n          -  Co-infection with hepatitis A, hepatitis C or HIV\n\n          -  Concomitant treatment with telbivudine\n\n          -  Pregnant or lactating women"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Patients with chronic hepatitis B on treatment with Pegasys"
            }
        }, 
        "enrollment": {
            "#text": "130", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 15, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01667432", 
            "org_study_id": "ML25626"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Peginterferon alfa-2a", 
                "Interferon-alpha"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 5, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Pleven", 
                        "country": "Bulgaria", 
                        "zip": "5800"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Plovdiv", 
                        "country": "Bulgaria", 
                        "zip": "4002"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sofia", 
                        "country": "Bulgaria", 
                        "zip": "1407"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sofia", 
                        "country": "Bulgaria", 
                        "zip": "1612"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sofia", 
                        "country": "Bulgaria", 
                        "zip": "1431"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sofia", 
                        "country": "Bulgaria", 
                        "zip": "1606"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sofia", 
                        "country": "Bulgaria", 
                        "zip": "1527"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Stara Zagora", 
                        "country": "Bulgaria", 
                        "zip": "6000"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Varna", 
                        "country": "Bulgaria", 
                        "zip": "9010"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": "Bulgaria"
        }, 
        "number_of_groups": "1", 
        "official_title": "A Multicenter, Prospective, Observational, Non-Interventional Study Evaluating On-Treatment Predictors of Response in Subjects With HBeAg Positive or HBeAg Negative Chronic Hepatitis B Receiving Therapy With PEGASYS\u00ae (Peginterferon Alfa-2a 40KD)", 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Bulgaria: Bulgarian Drug Agency"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Percentage of patients with suppression of HBV DNA < 2,000 IU/ml", 
                "safety_issue": "No", 
                "time_frame": "approximately 3 years"
            }, 
            {
                "measure": "In HBeAg positive patients: Percentage of patients who become HBeAg negative and anti-HBe positive", 
                "safety_issue": "No", 
                "time_frame": "approximately 3 years"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01667432"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "HBsAg clearance: Percentage of patients who become HBsAg negative", 
                "safety_issue": "No", 
                "time_frame": "approximately 3 years"
            }, 
            {
                "measure": "Correlation of HBsAg clearance with other on-treatment factors in HBeAg positive and HBeAg negative patients", 
                "safety_issue": "No", 
                "time_frame": "approximately 3 years"
            }, 
            {
                "measure": "Correlation of HBsAg clearance with pre-treatment factors in HBeAg positive and HBeAg negative patients", 
                "safety_issue": "Yes", 
                "time_frame": "approximately 3 years"
            }, 
            {
                "measure": "Incidence of serum ALT normalization: serum ALT/ALT ratio", 
                "safety_issue": "No", 
                "time_frame": "approximately 3 years"
            }, 
            {
                "measure": "Safety: Incidence of adverse events", 
                "safety_issue": "No", 
                "time_frame": "approximately 3 years"
            }
        ], 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2011", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}